MA-QUANTORI
20.7.2021 12:02:11 CEST | Business Wire | Press release
Quantori, a leading data science and digital transformation services company for the life sciences and healthcare sectors, today announced the appointment of Sean Murphy as Vice President of Client Services, effective immediately. Sean will oversee Quantori’s global network of IT professionals providing world-class software engineering and data analytics services to top biopharma and healthcare companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005589/en/
“Sean has a strong track record of leading cross-functional teams to deliver innovative digital IT solutions that support a seamless digital transformation experience,” said Richard Golob, CEO of Quantori. “As we enter our next phase of growth, we are thrilled to welcome Sean aboard to ensure delivery of cost-effective, high-quality data science and software engineering services.”
Sean has held various leadership positions at AstraZeneca and Thermo Fisher Scientific, where he focused primarily on R&D IT and Cloud and Digital Transformations. At AstraZeneca, Sean designed, developed, and led the Application Lifecycle Services organization, a world-class software engineering team that delivers quality products and services throughout AstraZeneca. He also was instrumental in establishing captive offshore development centers for AstraZeneca.
Most recently, Sean served as Vice President at General Electric, where he was the Technology Leader for the business and digital transformation of corporate systems. He focused predominately on the implementation of the enterprise SaaS solution Workday across all General Electric businesses.
Sean received his B.S. degree in Business Administration from the University of New Hampshire and his M.Sc. degree in Management with a specialization in Biopharmaceutical Leadership from Emmanuel College. He currently serves as a board member of the United Nations Association of Greater Boston and has served as a board member of the Society for Information Management of Boston and Newton Girls Soccer.
“I’m excited to join the highly impressive Quantori leadership team to help deliver nextgen data science and software solutions that provide immediate value for our clients,” according to Sean. “While at AstraZeneca, I had the pleasure of working with some of the professionals who are now Quantori’s leaders. They were the only service providers who truly understood the drug development process and the scientific problems we were trying to solve. I was so impressed with their performance and ability to deliver that I wanted to join the team!”
Quantori’s executive leadership boasts a rich history in the life sciences and healthcare IT industry. CEO Richard Golob, Chief Scientific Officer Yuriy Gankin, Ph.D., and Chief Technology Officer Vitaliy Aronov have successfully joined forces for more than two decades to deliver award-winning software engineering and data analytics services to top pharmaceutical companies and research organizations around the globe. They previously cofounded GGA Software Services, which was acquired by EPAM Systems in 2014. Golob built EPAM’s Life Sciences Business Unit into the fastest growing unit at the company.
“What we’ve experienced over the past year is that our clients require a versatile digital IT services provider that understands their needs for scalability and flexibility and has deep domain and data science knowledge, and Quantori checks all these boxes,” said Yuriy Gankin, Chief Scientific Officer at Quantori. “Sean’s background in helping organizations navigate the digital revolution will be invaluable in helping us fulfill our mission to empower our clients to achieve their strategic business goals.”
Quantori’s global headquarters are located in Cambridge, Massachusetts, with additional offices in London, U.K., St. Petersburg, Russia, and Tbilisi, Georgia. The company serves leading research institutions and biopharma organizations, including Bruker, The Jackson Laboratory, Perkin Elmer, and Takeda. Quantori’s team is currently more than 400 professionals, and the company is actively seeking qualified experts globally to keep pace with its rapid growth. For more information, please visit www.quantori.com or email info@quantori.com .
“The robust software engineering, scientific informatics and data science capabilities that Quantori offers have enabled us to achieve our IT strategy by harnessing the power of innovative digital technologies,” said Scott Thomas, Vice President of Information Technology for the LGC Genomics Division. “The COVID-19 pandemic has significantly increased demand for genomic analysis, and Quantori’s digital solutions have helped optimize our operations to meet the demand for these mission-critical applications.”
About Quantori
Quantori is transforming life sciences and healthcare with the power of digital IT. The company develops bespoke IT and data science solutions for accelerating research and drug discovery and improving healthcare delivery. Quantori combines data engineering and advanced analytics with scientific knowledge management and best-in-class software engineering to help life science and healthcare companies successfully achieve their digital transformations with greater speed and agility. Learn more at www.quantori.com and connect on social media @Twitter , @LinkedIn , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 07:00:00 CEST | Press release
Galderma will present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases, skin longevity and real-world patient experiences New analyses from the Nemluvio® (nemolizumab) clinical development program will explore long-term data, in line with Galderma’s commitment to improving the outcomes that matter most to patients1-7 Galderma will also present new research on sensitive skin, dermatoporosis, and acne, evaluating more personalized management approaches and the role of skincare in maintaining barrier function, skin resilience, and longevity8-19 The company will also host educational activities, including a symposium on atopic dermatitis and prurigo nodularis, an Industry Expert Hub session on targeting cellular senescence for skin longevity, a Cetaphil® Innovation Forum and Meet-the-Expert sessions and masterclasses Together, these presentations reflect Galderma's commitment to advancing scientific understanding, helping to shape th
Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 07:00:00 CEST | Press release
Oticon Medical’s first rechargeable solution for Ponto sound processors Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By br
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release
Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom